How to use the speech recognition tool?

NCT03319849

A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2

A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2.

Type: Interventional



Status of the trial: Active, Not recruiting

Orphan Drug Recognition: NA

Inclusion

  • Opening Date: 2018-02-06
  • Closing Date: 2022-03-31

Criteria

More information

Children: Yes

Adults: Yes

Funder Type: industry

HCP: Principal investigators

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: